6961 102 AUS 26 17 5

HFA 305

FREEDOM OF INFORMATION SUMMARY

ANTIROBE Capsules (clindamycin hydrochloride)

Supplemental NADA 120-161 Pharmacia & Upjohn Co.

Addition of a Dose Range for Dogs Addition of a 300 mg Capsule Addition of Recent MIC Data

Table of Contents

General Information	Page 3
Effectiveness	Page 4.
Target Animal Safety	Page 5.
Human Safety	Page 5.
Agency Conclusions	Page 5.
Approved Product Labeling	Page 6.

1. GENERAL INFORMATION

a. File Number:

NADA 120-161

b. Sponsor:

Pharmacia & Upjohn Co.

7000 Portage Road

Kalamazoo, MI 49001-0199 Drug Labeler Code: 000009

c. Established Name:

clindamycin hydrochloride

d. Proprietary Name:

ANTIROBE Capsules

e. Dosage Form:

capsules

f. How Supplied:

The product is available as follows:

25 mg – bottles of 600 75 mg – bottles of 200 150 mg – bottles of 100

150 mg - blister packages of 100

300 mg - blister packages of 100 (new)

g. How Dispensed:

Prescription (Rx) – US Federal law restricts this drug to use by, or on the order of, a

licensed veterinarian.

h. Amount of Active Ingredients:

Each capsule (4 strengths) contains the equivalent of 25, 75, 150, and 300 mg of

clindamycin hydrochloride

i. Route of Administration:

oral

j. Species/Class:

dogs

k. Recommended Dosage:

The drug is administered at a dose range of 2.5-15 mg/lb every 12 hours for skin infections (wounds and abscesses), deep wounds and abscesses, and dental infections for a maximum of 28 days. The drug is also administered at a dose range of 5.0-15 mg/lb every 12 hours for osteomyelitis for a

minimum of 28 days.

1. Pharmacological Category:

m. Indications:

antibiotic

ANTIROBE Capsules (brand of clindamycin hydrochloride) are indicated for the treatment of infections in dogs caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Skin infections (wounds and abscesses) due

Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius).

Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

n. Effect of Supplement:

The supplement provides for the use of clindamycin hydrochloride (ANTIROBE Capsules) in dogs at a dose range of 2.5-15 mg/lb body weight every 12 hours for skin infections (wounds and abscesses), deep wounds and abscesses, and dental infections. It also provides for a dose range in dogs of 5-15 mg/lb every 12 hours for osteomyelitis. In addition, this supplement provides for the addition of a 300 mg capsule. This supplement also provides for the addition of recent MIC data derived from U.S. diagnostic laboratories.

2. EFFECTIVENESS

Please refer to the Freedom of Information (FOI) Summaries for ANTIROBE Capsules (clindamycin hydrochloride), NADA 120-161, dated June 6, 1984 and November 16, 1989. This approval does not affect this section of these summaries, however, a review

of this data supports the lower ends of the two dose ranges of 2.5-15 mg/lb and 5-15mg/lb body weight every 12 hours in dogs.

3. TARGET ANIMAL SAFETY

Please refer to the Freedom of Information (FOI) Summary for ANTIROBE Capsules (clindamycin hydrochloride), NADA 120-161, dated June 6, 1984. This approval does not affect this section of the summary, however, a review of this data supports the upper end of the two dose ranges of 2.5-15 mg/lb and 5-15 mg/lb body weight every 12 hours for up to a maximum of 28 days in dogs.

4. HUMAN SAFETY

This drug is intended for use in dogs, which are non-food animals. Because this new animal drug is not intended for use in food-producing animals, data on human safety pertaining to drug residues in food were not required for approval of this NADA.

Human Warnings are provided on the product label as follows: "WARNING: Keep out of reach of children. Not for human use."

5. AGENCY CONCLUSIONS

The data submitted in support of this supplemental NADA satisfy the requirements of Section 512 of the Federal Food, Drug, and Cosmetic Act and 21 CFR 514 of the implementing regulations. The data demonstrates that ANTIROBE Capsules (clindamycin hydrochloride), when administered to dogs, are safe and effective when used under labeled conditions.

The drug is restricted to use by or on the order of a licensed veterinarian because professional expertise is judged to be critical in the diagnosis of bacterial infections in animals, treatment of these conditions, and monitoring for possible adverse effects of the drug.

Under the Center's supplemental approval policy 21 CFR 514.106(b)(2), this is a Category II change.

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act, this approval for non-food producing animals does not qualify for marketing exclusivity because the supplemental application does not contain substantial evidence of the effectiveness of the drug involved, or any studies of animal safety required for the approval and conducted or sponsored by the applicant.

6. APPROVED PRODUCT LABELING

Facsimile Labeling is attached as indicated below:

Package insert

Bottle labels (25 mg, 75 mg, 150 mg)

Blister package labels (150 mg, 300 mg)

Blister package box labels (150 mg, 300 mg)

Antirobe®

brand of clindamycin hydrochloride capsules, USP

Pharmacia &Upjohn

Antirobe Aquadrops®

brand of clindamycin hydrochloride liquid





Antirobe

brand of clindamycin hydrochloride capsules, USP

Antirobe Aquadrops

brand of clindamycin hydrochloride liquid

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

ANTIROBE Capsules and ANTIROBE AQUADROPS Liquid contain clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by Streptomyces lincolnensis var. lincolnensis.

ANTIROBE Capsules (For Use in Dogs Only): 25 mg Capsule, each yellow and white capsule contains clindamycin hydrochloride equivalent. to 25 mg of clindamycin.

75 mg Capsule, each green capsule contains clindamycin hydrochloride equivalent to 75 mg of clindamycin.

150 mg Capsule, each light blue and green capsule contains clindamycin hydrochloride equivalent to 150 mg of clindamycin.

300 mg Capsule, each light blue capsule contains clindamycin hydrochloride equivalent to

300 mg of clindamycin.

ANTIROBE AQUADROPS Liquid (For Use in Dogs and Cats) is a palatable formulation intended for oral administration. Each mL of ANTIROBE AQUADROPS Liquid contains clindamycin hydrochloride equivalent to 25 mg clindamycin; and ethyl alcohol, 8.64%.

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

MICROBIOLOGY: Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The minimum inhibitory concentrations (MICs) of Grampositive and obligate anaerobic pathogens isolated from dogs and cats in the United States are presented in Table 1 and Table 2. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS).

Antirobe

brand of clindamycin hydrochloride capsules, USP

Antirobe Aquadrops

brand of clindamycin hydrochloride liquid

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-991

Organism	Number					
	of isolates	MIC ₅₀	MICES	MIC 90	Range	
Soft Tissue/Wou	nd²					
Staphylococcus	\$					
aureus	17	0.5	0.5	≥4.0	0.25-≥4.0	
Staphylococcus						
intermedius	28	0.25	0.5	≥4.0	0.125-24.0	
Staphylococcus		2.2		1.11		
sop.	18	0.5	0.5	≥4.0	0.25•≥4.0	
Beta-hemolytic				≥4.0		
streptococci	46	0.5	0.5	24.0	0.25-24.0	
Streptococcus	11	0.5	≥4.0		0.25-≥4.0	
spp.	11	0.5	24.0	≥4.0	0.25-24.0	
Osteomyelitis/Bo	ne3					
Staphylococcus						
aureus	20	0.5	0.5	0.5	0.54	
Staphylococcus						
intermedius	15	0.5	≥4.0	≥4.0	0.25-24.0	
Staphylococcus						
spp.	18	0.5	≥4.0	≥4.0	0.25-24.0	
Beta-hemolytic						
streptococci	21	0.5	2.0	2.0	0.25-≥4.0	
Streptococcus						
spp.	21	≥4.0	≥4.0	≥4.0	0.25-≥4.0	
Dermal/Skin 5						
Staphylococcus						
aureus	25	0.5	≥4.0	≥4.0	0.25-≥4.0	
Staphylococcus						
intermedius	48	0.5	24.0	≥4.0	0.125-≥4.0	
Staphylococcus						
spp.	32	0.5	≥4.0	≥4.0	0.25 • ≥4.0	
Beta-hemolytic				- :•		
streptococci	17	0.5	0.5	0.5	0.25-0.5	

- 1 The correlation between the in vitro susceptibility data and clinical response has not been determined.
- Soft Tissue/Wound: Includes samples labeled wound. abscess, aspirate, exudates, draining tract, lesion, and
- 3 Osteomyelitis/Bone: Includes samples labeled bone.
- fracture, joint, tendon 4 No range, all isolates yielded the same value
- 5 Dermal/Skin: includes samples labeled skin, skin swab, blopsy, incision, lip

Antirobe

brand of clindamycin hydrochloride capsules, USP

Antirobe Aquadrops

brand of clindamycin hydrochloride liquid

Table 2. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Feline Pathogens from Wound and Abscess Samples in the U.S. during 19981

Organism	Number of Isolates	MIC 50	MIC 50	Range
Bacteroides/ Prevotella	30	0.06	4.0	≤0.015-4.0
Fusobacterium spp.	17	0.25	0.25	≤0.015⋅0.5
Peptostrepto- coccus spp.	18:	0.13	0.5	≤0.015-8.0
Porphyromonas spp.	13	0.06	0.25	≤0.015-8.0


1 The correlation between the in vitro susceptibility data and clinical response has not been determined,

PHARMACOLOGY

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

Dog Serum Levels: Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

> Clindamycin Serum Concentrations 2.5 mg/lb (5.5 mg/kg) After B.I.D. Oral Dose of Antriobe Capsules to Dogs



Antirobe


brand of clindamycln hydrochloride capsules, USP

Antirobe Aquadrops

brand of clindamycin hydrochloride liquid

Cat Serum Levels: Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 5 mg/lb of clindamycin hydrochloride liquid every 24 hours. The average peak serum concentration of clindamycin occurs approximately 1 hour after oral dosing. The elimination half-life of clindamycin in feline serum is approximately 7.5 hours. In healthy cats, minimal accumulation occurs after multiple oral doses of clindamycin hydrochloride, and steady-state should be achieved by the third dose.

Clindamycin Serum Concentrations 5 mg/lb (11 mg/kg) After Single Oral Dose of Antirobe Aquadrops to Cats



METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after ANTIROBE product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites. especially N-dimethyl clindamycin and clindamycin sulfoxide.

ANIMAL SAFETY SUMMARY

Rat and Dog Data: One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride capsules to be well tolerated. Differences did not occur in the

Antirobe®

brand of clindamycin hydrochloride capsules, USP

Antirobe Aquadrops®

brand of clindamycin hydrochloride liquid

parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gall bladder.

Safety in gestating bitches or breeding males has not been established.

Cat Data: The recommended daily therapeutic dose range for clindamycin hydrochloride (ANTIROBE AQUADROPS Liquid) is 11 to 33 mg/kg/day (5 to 15 mg/lb/day) depending on the severity of the con-dition. Clindamycin hydrochloride (ANTIROBE AQUADROPS Liquid) was tolerated with little evidence of toxicity in domestic shorthair cats when administered orally at 10x the minimum recommended therapeutic dally dose (11 mg/kg; 5 mg/lb) for 15 days, and at doses up to 5x the minimum recommended therapeutic dose for 42 days. Gastrointestinal tract upset (soft feces to diarrhea) occurred in control and treated cats with emesis occurring at doses 3x or greater than the minimum recommended therapeutic dose (11 mg/ kg/day; 5 mg/lb/day). Lymphocytic inflammation of the gallbladder was noted in a greater number of treated cats at the 110 mg/kg/day (50 mg/lb/ day) dose level than for control cats. No other effects were noted. Safety in gestating queens or breeding male cats has not been established.

INDICATIONS

ANTIROBE (brand of clindamycin hydrochloride) Capsules (for use in dogs only) and AQUADROPS Liquid (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dogs: Skin Infections (wounds and abscesses) due to coagulase positive staphylococic (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium

Antirobe

brand of clindamycin hydrochloride capsules, USP

Antirobe Aquadrops

brand of clindamycin hydrochloride liquid

necrophorum and Clostridium perfringens. Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens. Osteomyelitls due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Cats: Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and Infections due to Clostridium perfringens and Bacteroides fragilis.

Dental Infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

CONTRAINDICATIONS

ANTIROBE Capsules and ANTIROBE AQUA-DROPS Liquid are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

WARNINGS

Keep out of reach of children. Not for human use.

PRECAUTIONS

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of ANTIROBE occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of ANTIROBE should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ANTIROBE should be used with caution in animals receiving such aceste.

Safety in gestating bitches and queens or breeding male dogs and cats has not been established.

ADVERSE REACTIONS

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

To report adverse reactions or a suspected adverse reaction call 1-800-793-0596.

Antirobe

brand of clindamycin hydrochloride capsules, USP

Antirobe Aquadrops

brand of clindamycin hydrochloride liquid

DOSAGE AND ADMINISTRATION

Dogs:

Infected Wounds, Abscesses, and Dental Infections

Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ANTIROBE products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Dosage Schedule:

Capsules

ANTIROBE 25 mg, administer 1-6 capsules every 12 hours for each 10 pounds of body weight.

ANTIROBE 75 mg, administer 1-6 capsules every 12 hours for each 30 pounds of body weight.

ANTIROBE 150 mg, administer 1-6 capsules every 12 hours for each 60 pounds of body weight.

ANTIROBE 300 mg, administer 1-6 capsules every 12 hours for each 120 pounds of body weight.

Liquid

ANTIROBE AQUADROPS, administer 1-6 mL/10 lbs body weight every 12 hours.

Dogs:

Osteomyelitis

Oral: 5.0-15.0 mg/lb body weight every 12 hours

Duration: Treatment with ANTIROBE is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

Dosage Schedule:

Capsules

ANTIROBE 25 mg, administer 2-6 capsules every 12 hours for each 10 pounds of body weight.

ANTIROBE 75 mg, administer 2-6 capsules every 12 hours for each 30 pounds of body weight.

ANTIROBE 150 mg, administer 2-6 capsules every 12 hours for each 60 pounds of body weight

ANTIROBE 300 mg, administer 2-6 capsules every 12 hours for each 120 pounds of body weight.

Liquid

ANTIROBE AQUADROPS, administer 2-6 mL/ 10 lbs body weight every 12 hours.

Cats

Infected Wounds, Abscesses, and Dental Infections

5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition. Duration: Treatment with ANTIROBE AQUADROPS Liquid may be continued up to a

Antirobe

brand of clindamycin hydrochloride capsules, USP

Antirobe Aquadrops

brand of clindamycin hydrochloride liquid

maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule:

ANTIROBE AQUADROPS, to provide 5.0 mg/lb, administer 1 mL/5 lbs body weight once every 24 hours; to provide 15.0 mg/lb, administer 3 mL/5 lbs body weight once every 24 hours.

HOW SUPPLIED

ANTIMODE Capsules are available as.	
25 mg - bottles of 600NDC 0009-3043-01	
75 mg - bottles of 200NDC 0009-3044-01	
50 mg - bottles of 100NDC 0009-3045-01	

150 mg - blister packages of 100NDC 0009-3045-08

300 mg - blister packages of 100NDC 0009-5015-01

NADA #120-161, Approved by FDA ANTIROBE AQUADROPS Liquid is available as

ANTIHOBE AQUADHOPS Liquid is available as 20 mL filled in 30 mL bottles (25 mg/mL) supplied in packers containing 12 cartoned bottles with direction labels and calibrated dosing droppers, NDC 0009-3179-01. NADA #135-940, Approved by FDA

To report a suspected adverse reaction or to request a material safety data sheet (MSDS), call 1-800-793-0596.

Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].

ANTIROBE AQUADROPS

Made by

Pharmacia & Upjohn Company Kalamazoo, MI 49001, USA

ANTIROBE Capsules
Made in Canada for
Pharmacla & Upjohn Company
Kalamazoo, Mi 49001, USA
By Patheon YM Inc.
Don Mills, Ontario, M3B 1Y5
CANADA

Revised February 2002

813 805 711E 692074 3179-01-000

Approved for use in dogs

Recommended dosage: For therapy of wounds, abscesses, and 10 pounds body weight every 12 hours dental infections, 1-6 capsules for each

See package insert for complete body weight every 12 hours. For therapy of osteomyelitis, 2-6 capsules for each 10 pounds

product information. Warning—Keep out of reach of

Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].

Keep container tightly closed. children. Not for human use.

Each capsule contains:
Clindamycin hydrochloride equivalent to clindamycin, 25 mg.

812 771 108B 5719-25/2

600 Capsules NDC 0009-3043-01

Antirobe® Capsules

clindamycin hydrochloride capsules, USP

3

Equiv. to 25 mg clindamycin

restricts this drug to use by or on the order of a licensed veterinarian. Caution: Federal (USA) law For Use in Dogs Only

NADA #120-161, Approved by FDA



Open Here

WUDIONN Pharmacia



30 pounds body weight every 12 hours. 2-6 capsules for each For therapy of osteomyelitis body weight every 12 hours abscesses, and denta for each 30 pounds For therapy of wounds Recommended dosage: Approved for use in dogs intections, 1-6 capsules 200 Capsules NDC 0009-3044-01

Antirobe

Capsules

clindamycin hydrochloride capsules, USP

See package insert for

complete product

information.

Equiv. to 75 mg clindamycin

For Use in Dogs Only

temperature 20° to 25° C (68° to 77° F) [see USP].

Store at controlled room

closed

Keep container tightly

Not for human use

of children.

Warning—Keep out of reach

the order of a licensed veterinarian. restricts this drug to use by or on Caution: Federal (USA) law

equivalent to clindamycin Clindamycin hydrochloride Each capsule contains:

NADA #120-161, Approved by FDA

812 765 106B 5719-26/2

N 3

Open Here

unoldny Pharmacia



Recommended dosage: and dental infections, 1-6 capsules for each 60 pounds body weight every or therapy of wounds, abscesses Approved for use in dogs or therapy of osteomyelitis 2 hours

See package insert for body weight every 12 hours 2-6 capsules for each 60 pounds lot for human use Varning—Keep out of reach of children (eep container tightly closed omplete product information

emperature 20° to 25° C Store at controlled room 68° to 77° F) [see USP].

equivalent to clindamycin, 150 mg Clindamycin hydrochloride Each capsule contains:

5719-21/2 B12 774 106B

100 Capsules **NDC** 0009-3045-01

Intirobe®

Capsules

clindamycin hydrochloride capsules, USP

For Use in Dogs Only Equiv. to 150 mg clindamycin on the order of a licensed veterinarian. Caution: Federal (USA) law NADA #120-161, Approved by FDA estricts this drug to use by or


N 3

Pharmacia



3 9

Open Here



Antirobe® 150 mg clindamycin hydrochloride capsules, USP LOT 000XX Pharmacia & Upjohn Co. EXP 00/0000 Kalamazoo, MI 49001



0009304508

Antirobe® 150 mg clindamycin hydrochloride capsules, USP LOT 000XX Pharmacia & EXP 00/0000 Upjohn Co.

0009304508

Antirobe® 150 mg clindamycin hydrochloride capsules, USP

LOT 000XX Pharmacia & EXP 00/0000 Upjohn Co.

0009304508

Antirobe® 150 mg clindamycin hydrochloride capsules, USP Pharmacia &

LOT 000XX EXP 00/0000 Upjohn Co. Kalamazoo, MI 49001



Antirobe® 150 mg clindamycin hydrochloride capsules, USP LOT 000XX Pharmacia & EXP 00/0000 Upjohn Co.

Kalamazoo, MI 49001



0009304508

8057026000

Uplohn Co. EXP 00/0000 Pharmacia & **LOT 000XX** capsules, USP

clindamycin hydrochloride

Antirobe® 150 mg

8057026000


Oplopu Co. EXP 00/0000 Pharmacia & LOT 000XX capsules, USP clindamycin hydrochloride

Antirobe® 150 mg



Opjohn Co. FXh 00\0000 Pharmacia & **LOT 000XX** capsules, USP clindamycin hydrochloride

Antirobe® 150 mg






Upjohn Co. EXP 00/0000 Pharmacia & LOT 000XX capsules, USP clindamycin hydrochloride

Antirobe® 150 mg



Upjohn Co. EXP 00/0000 Pharmacia & **LOT 000XX** cspsules, USP clindamycin hydrochloride Antirobe® 150 mg



Antirobe® 300 mg clindamycin hydrochloride capsules, USP

Pharmacia & Upjohn Co. LOT 00XXX EXP 00/0000

Kalamazoo, MI 49001



Antirobe® 300 mg clindamycin hydrochloride capsules, USP

Pharmacia & Upjohn Co. LOT 00XXX EXP 00/0000

Kalamazoo, MI 49001



Antirobe® 300 mg clindamycin hydrochloride capsules, USP

Pharmacia & Upjohn Co.

LOT 00XXX EXP 00/0000

Kalamazoo, MI 49001



Antirobe® 300 mg clindamycin hydrochloride capsules, USP

Pharmacia & Upjohn Co. LOT 00XXX EXP 00/0000

Kalamazoo, MI 49001



Antirobe® 300 mg clindamycin hydrochloride capsules, USP

Pharmacia & Upjohn Co.

LOT 00XXX EXP 00/0000

Kalamazoo MI 49001





Pharmacia & LOT 00XXX Upjohn Co. Kalamazoo, MI 49001

en 300 PedoritnA BedoritnA Belinds Bel



Pharmacia & LOT 00XXX Upjohn Co. EXP 00/0000 Kalamazoo, MI 49001

Antirobe® 300 mg clindamycin hydrochloride capsules, USP



Pharmacia & LOT 00XXX Upjohn Co. Kalamazoo, MI 49001

Antirobe® 300 mg clindamycin hydrochloride capsules, USP



Pharmacia & EXP 00/0000 Valenazoo, MI 49001

Antirobe® 300 mg clindamycin hydrochloride capsules, USP



Pharmacia & LOT 00XXX Upjohn Co. EXP 00/0000 Kalamazoo, MI 49001

Antirobe[®] 300 mg clindamycin hydrochloride capsules, USP